Adium
Adium Pharma S.A. is a Uruguay-headquartered pharmaceutical company that commercializes and distributes innovative therapeutics from global pharma partners across 18 Latin American countries, spanning 15 therapeutic areas including oncology, cardiology, and rare diseases.
- Company typePrivate
- Founded1970
- HeadquartersMontevideo, Uruguay
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Adium does
Adium Pharma S.A. is a privately held Uruguayan pharmaceutical company headquartered in Montevideo that operates as a regional commercialization and distribution partner for global innovative pharmaceutical and biotechnology companies across Latin America. With more than 50 years of operating history and own operations in 18 Latin American countries, Adium markets and distributes a broad portfolio of therapeutics spanning 15 areas including cardiology, diabetes, oncology, neurology, hematology, rare diseases, immunology, and psychiatry. The company's revenue model is built primarily on licensing and distribution agreements with originator companies (Pfizer, Eli Lilly, Amgen, Regeneron, Moderna, Astellas, PharmaMar, Y-mAbs, Jazz Pharmaceuticals, Debiopharm), under which Adium provides regulatory registration, market access, sales force deployment, medical affairs, pharmacovigilance, and supply chain services. Notable recent commercial wins include exclusive distribution of Regeneron's cemiplimab (LIBTAYO®) in Brazil and a COVID-19 vaccine distribution partnership with Moderna across the region.
Adium's underlying technology stack centers on pharmaceutical manufacturing executed under a Quality by Design approach, with production plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay holding certifications from local and international regulatory authorities. The R&D function employs pharmacists, chemists, biochemists, research engineers, and process technicians to support formulation and clinical studies. Manufacturing services are offered both for Adium's own portfolio and for partner products, including secondary packaging. A documented Pharmacovigilance System governs patient safety processes across the organization. The company also operates Vertismed, a digital platform for medical-scientific content targeted at healthcare professionals.
The go-to-market is sales-led and B2B in nature: Adium serves as the regional gateway for global innovators, combining a high-impact sales force specialized in high-tech products with Market Access teams (for pricing and reimbursement), Medical Affairs teams (for continuous medical education), and compliance infrastructure. Pricing is not publicly disclosed and follows regional regulatory frameworks. The company targets healthcare professionals and patients across Latin America through its 18-country commercial footprint, supported by a LinkedIn presence and the Vertismed platform for medical engagement.
Adium firmographics
Firmographics- Name
- Adium
- Legal name
- Adium Pharma S.A.
- Website
- https://adiumpharma.com
- Company type
- Private
- Founded year
- 1970
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Adium Pharma S.A. is a Uruguay-headquartered pharmaceutical company that commercializes and distributes innovative therapeutics from global pharma partners across 18 Latin American countries, spanning 15 therapeutic areas including oncology, cardiology, and rare diseases.
- Ownership category
- akta.pro rank
Adium industry classification
Industry- Product category
- Pharmaceutical Distribution and Manufacturing
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA), Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
Keywords
Where Adium is headquartered
LocationHeadquarters
- HQ city
- Montevideo
- HQ country
- Uruguay
- HQ region
- Latin America
Offices5 records
Markets served
Adium business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Marketing or Sales, Supply Chain, Technology or R&D, Infrastructure
Revenue model
- Pharmaceutical Distribution and Commercialization: Adium generates revenue by partnering with global innovative pharmaceutical and biotechnology companies to promote and distribute their products across Latin America. The company operates as a commercial partner, leveraging its regional presence, regulatory expertise, supply chain capabilities, and sales force to commercialize products from licensors throughout the region.
- Manufacturing Services: Secondary packaging plants and production capabilities across multiple Latin American countries, serving both own portfolio and partner products
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Adium product offering
Product offeringCore offering
Adium is a pharmaceutical company operating in 18 Latin American countries that manufactures, distributes, and commercializes a broad portfolio of therapeutic products across 15 specialty areas including cardiology, diabetes, oncology, neurology, and rare diseases. The company serves as the regional commercial partner and 'gateway to innovation' for global pharmaceutical and biotechnology companies seeking to expand into Latin America, providing regulatory, supply chain, manufacturing, sales force, market access, and pharmacovigilance capabilities. It also operates its own manufacturing plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay.
Product overview
Adium is a leading pharmaceutical company in Latin America with over 50 years of experience, offering a broad portfolio of high-quality therapeutic solutions across 15 therapeutic areas including Cardiology, Diabetes, Oncology, Neurology, Hematology, and Rare Diseases. The company operates as both a pharmaceutical product provider and a regional partner of choice for global biotech and innovative companies seeking to expand into Latin America. Adium's portfolio includes products for pain treatment, obesity, osteoporosis, gynecology, gastroenterology, immunology, psychiatry, and urology. Beyond product commercialization, Adium provides integrated services including manufacturing (with plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay), research and development, pharmacovigilance, regulatory support, supply chain, and market access capabilities. The company also offers Vertismed, a medical-scientific content platform.
Differentiator
Problem solved
Functional benefit
Brands
- Vertismed: A platform for medical-scientific content with more than 40 articles, 21 3D objects, and interactive books.
Products and services
- Cardiology Products Pharmaceutical products for the treatment of hypertension, hypercholesterolemia, and anticoagulation targeting cardiovascular diseases, the leading cause of death in Latin America.
- Diabetes Products Pharmaceutical products for the treatment of Type I and Type II Diabetes, addressing one of the main causes of death and disability in Latin America.
- Oncology Products Broad portfolio of medications aimed at combating various types of cancer affecting lung, breast, pancreas, or bile ducts.
- Rare Diseases Products Medications to treat diseases including paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, cystic fibrosis, and idiopathic pulmonary fibrosis.
- Neurology Products Modern and effective molecules for treatment of patients with Alzheimer's disease, epilepsy, and Parkinson's.
- Pain Treatment Products Leading molecules for acute and chronic pain treatment aimed at improving quality of life by reducing patient suffering.
- Hematology Products Biotechnology-derived innovative molecules to treat blood diseases including anemia, thrombopathies, lymphomas, hemophilia, and leukemia.
- Immunology Products Drugs with target molecules for treatment of immune diseases including rheumatoid arthritis, multiple sclerosis, and myasthenia gravis.
- Gynecology Products Wide range of contraceptives, both oral and devices, focusing on women's health through the study of the female reproductive system.
- Obesity Treatment Products Different molecules and combinations to help achieve desired goals in obesity treatment, addressing the complex disease of excessive body fat.
- Osteoporosis Products Innovative portfolio for treatment and prevention of osteoporosis and osteopenia, reducing fracture risks for older adults.
- Psychiatry Products Multiple therapeutic alternatives for the treatment of psychiatric conditions manifesting as disturbances in thought, emotions, or behavior.
- Urology Products Innovative medications for overactive bladder, benign prostatic hyperplasia, and erectile dysfunction.
- Osteoarticular Products Medications and devices for degenerative joint disease including successful combinations and viscosupplementation devices.
- Gastroenterology Products Effective molecules for the treatment of peptic ulcer disease and irritable bowel syndrome caused by bacteria, parasites, viruses, or certain foods.
- Manufacturing Services Production centers in Argentina, Paraguay, Brazil, Mexico, and Uruguay governed by highest standards of quality and efficiency, equipped with state-of-the-art technology and holding certifications from prominent local and international regulatory authorities.
- Research and Development Services Quality by Design approach in product development with multidisciplinary team including pharmacists, chemists, biochemists, research engineers, and process technicians, investing in clinical studies to support production of safe and effective medicines.
- Pharmacovigilance Services Documented processes, activities, and procedures ensuring functioning of Pharmacovigilance System for patient safety.
- Vertismed Medical-scientific content platform featuring more than 40 articles, 21 3D objects, and interactive books for healthcare professionals.
Quantifiable outcome
- Broad therapeutic portfolio covering 14+ specialty areas
Companies that use Adium
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles2 records
Adium technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Adium partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core.
- RegeneroncoreAdium announced exclusive distribution agreement with Regeneron to commercialize CEMIPLIMAB (LIBTAYO®) in Brazil, demonstrating Adium's role as a key distribution partner for global innovative pharmaceutical products in Latin America.
- Moderna Inc.coreAdium reached an important agreement with Moderna Inc. to collaborate in the distribution and commercialization of COVID-19 vaccines in Latin America.
- Eli LillycoreLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
- AmgencoreLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
- PfizercoreLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
- DebiopharmcoreLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
- AstellascoreLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
- PharmaMarcoreLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
- Y-mAbscoreLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
- Jazz PharmaceuticalscoreLicensor partner - one of more than a dozen leading multinational research and biotechnology companies that Adium represents through solid alliances and long-term agreements.
Scale indicators3 records
Recent moves5 records
Expansion highlights3 records
Adium competitors and assessment
Company assessmentDirect peers
- Laboratorios Roemmers: Argentine pharmaceutical group with broad presence across Latin America in cardiology, neurology, and other specialty areas, with own manufacturing. Comparable to Adium as a Southern Cone-anchored LatAm pharma with multi-country distribution.
- Laboratorios Bagó: Argentine pharmaceutical group with operations throughout Latin America in cardiology, central nervous system, and other specialty areas. Comparable as a Southern Cone multi-country pharma with partner-distribution model.
- Genfar (Sanofi): Multi-Latin pharmaceutical company (now part of Sanofi) historically focused on generics and specialty across Latin America. Comparable to Adium in its pan-regional LatAm pharmaceutical distribution model.
- Eurofarma Laboratórios: Brazilian-headquartered pharmaceutical company with multi-country Latin American presence, manufacturing footprint, and portfolio spanning branded specialty, generics, and OTC. Directly comparable to Adium as a regional LatAm pharma platform with own manufacturing and partner distribution.
- Aché Laboratórios Farmacêuticos: Brazilian pharmaceutical company with growing presence across Latin America across prescription, generics, and OTC categories, with own manufacturing plants. Comparable in therapeutic breadth and LatAm multi-country footprint.
Regional players
- Biolab Farmacêutica: Brazilian pharmaceutical company with cardiovascular and specialty focus expanding across Latin America. Comparable as a regional pharma with branded specialty portfolio in cardiology, an area where Adium is also heavily exposed.
- EMS Pharma: Brazilian pharmaceutical leader with extensive generics and branded portfolio and growing Latin American reach. Comparable to Adium as a regional LatAm pharma, though primarily Brazil-anchored.
- Glenmark Pharmaceuticals (LatAm): India-headquartered pharmaceutical company with established Latin American commercial footprint in specialty, dermatology, and respiratory. Comparable as a regional pharma expanding via licensing/distribution partnerships in LatAm.
Broad incumbents
- Bayer (Pharmaceuticals, LatAm): Global pharmaceutical major with deep own operations across Latin America in cardiology, women's health, and specialty. Comparable as a multinational with direct LatAm commercialization capabilities that competes with and also partners with regional players like Adium.
- Teva Pharmaceutical (LatAm): Global generics and specialty pharmaceutical company with established commercial presence in Latin America. Comparable as a partner/distributor model across multiple LatAm countries in specialty and generics.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Adium social profiles
Digital presenceAdium financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adium leadership team
Management profileNumber of profiles
Adium funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adium M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adium
What does Adium do?
Adium is a pharmaceutical company operating in 18 Latin American countries that manufactures, distributes, and commercializes a broad portfolio of therapeutic products across 15 specialty areas including cardiology, diabetes, oncology, neurology, and rare diseases. The company serves as the regional commercial partner and 'gateway to innovation' for global pharmaceutical and biotechnology companies seeking to expand into Latin America, providing regulatory, supply chain, manufacturing, sales force, market access, and pharmacovigilance capabilities. It also operates its own manufacturing plants in Argentina, Paraguay, Brazil, Mexico, and Uruguay.
Is Adium a public or private company?
Adium is a private company. It is classified as unknown and is currently operating.
When was Adium founded?
Adium was founded in 1970. It employs 251 to 500 people.
Where is Adium based?
Adium is headquartered in Montevideo, Uruguay, in the Latin America region.
How does Adium make money?
Two revenue lines are on record. Pharmaceutical Distribution and Commercialization is the primary driver. The others are manufacturing Services.
Who are Adium's main competitors?
Direct peers on record are Laboratorios Roemmers, Laboratorios Bagó, Genfar (Sanofi), Eurofarma Laboratórios and Aché Laboratórios Farmacêuticos. Regional players are Biolab Farmacêutica, EMS Pharma and Glenmark Pharmaceuticals (LatAm). Broad incumbents are Bayer (Pharmaceuticals, LatAm) and Teva Pharmaceutical (LatAm).
Does Adium have an API?
No public API is recorded for Adium.
What industry is Adium in?
Adium's product category is Pharmaceutical Distribution and Manufacturing. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of CRAOAHAA, Prescription Pharmaceutical (Rx) Wholesale Distribution. Its NAICS code is 424210 and its SIC code is 5122.